The reduced expression of NFAT1 protein in Umbilical Cord Blood (UCB)-derived CD4+ T-cells and the corresponding reduction in inflammatory cytokine secretion following stimulation in part underlies their phenotypic differences from adult blood (AB) CD4+ T-cells. This muted response may contribute to the lower incidence and severity of high-grade acute graft-versus-host disease (aGVHD) exhibited by UCB grafts. Here we provide evidence that a specific microRNA, miR-184, inhibits NFAT1 protein expression elicited by UCB CD4+ T-cells. Endogenous expression of miR-184 in UCB is 58.4-fold higher compared to AB CD4+ T -cells, and miR-184 blocks production of NFAT1 protein through its complementary target sequence on the NFA Tc2 mRNA without transcript degradation. Furthermore, its negative effects on NFAT1 protein and downstream IL-2 transcription are reversed through antisense blocking in UCB and can be replicated via exogenous transfection of precursor miR-184 into AB CD4+ T-cells. Our findings reveal a previously uncharacterized role for miR-184 in UCB CD4+ T-cells and a novel function for microRNA in the early adaptive immune response.
INTRODUCTION
Numerous reports spanning two decades have confirmed umbilical cord blood (UCB) as a clinical source of hematopoietic progenitors for allogeneic transplantation in the treatment of hematologic malignancies 1,2. Despite the primary drawback of slower kinetics of myeloid engraftment as a result of limited graft cell dose 3 , UCB has several advantages over bone marrow (BM) in a therapeutic setting, particularly the obseNed lowered incidence of acute Graft-Versus-Host Disease (aGVHD) despite the infusion of HLA disparate grafts 4 . aGVHD remains a major obstacle to the broader application of allogeneic stem cell therapy and is characterized by donor CD4+ T-cell activation in response to self antigen presented by Class" MHC on host antigen presenting cells (APC). The clinical manifestation of aGVHD closely mimics the pathophysiology of autoimmune disorders with early secretion of pro-inflammatory cytokines including IFNy, TNFa 5 , GM-CSF, and IL-1, as well as later secretion of IL-2 by donor-derived Tcells. These stimulate inflammatory cell proliferation, upregulate MHC expression, NK and cytotoxic CDS+ T-cell recruitment, and widespread tissue damage particularly in the skin, large intestine, and Iiver 6 ,?
A key transcription factor in CD4 + T-cell activation and the downstream target of Cyclosporine A (CsA) treatment, Nuclear Factor of Activated T -cells 1 (NFAT1, mRNA: NFA Tc2) influences the expression of a wide array of cytokines 8 , surface receptors9, and cell cycle regulators 10 associated with normal and auto-immune responses ll . Tandem interactions with other transcription factors, particularly the AP1 (fos/jun) complex occur at adjacent DNA binding sites (WGGAAAWN for NFAT and TGAGTCA for AP1) located in the promoter regions of the genes encoding such factors as IFNy, TNFa., IL-2, IL-4, IL-5, CTLA-4, GM-CSF, and CD40L. Expression of many of these genes, specifically those associated with a Th2 or allergic response, is not severely diminished (and in some cases enhanced) in NFAT1-null mice, suggesting some level of redundancy among members of the NFAT family and their binding partners 12. However, NFAT1 has been shown to be required for the sustained production of IFN_y13, GM-CSF, IL-3, IL-4, IL-2 (with AP1)8.14, and TNF-a 8 , indicating a critical role for NFAT1 in the initiation of a productive Th1 immune response. In the absence of AP1, NFAT1 heterodimers may activate an alternate, anergic repertoire of T-cell gene expression 15,16. Previous work by our laboratory has demonstrated significantly reduced NFAT1 protein expression in resting and stimulated UCB CD4+ T-cells compared to adult blood (AB)17. This observation correlates with the severe reduction in IFNy, TNFa, and other cytokine production by UCB after primary stimulation. Microarray gene expression profiling revealed markedly lower expression of nearly all NFAT1-associated transcripts, but importantly, not the mRNA for NFAT1 (NFATc2) itself. Notably, UCB CD4+ T-cells express lower levels mRNA encoding GM-CSF, IFNy, TNFa, IL-3, IL-4, IL-5, IL-13, MIP-1a as well as the inflammatory surface markers CD40L, CTLA-4, and the IL-2 receptor alpha chain (CD25) 18 . As secretion of the aforementioned cytokines is strongly associated with the non-self recognition of recipient APC by donor CD4+ Tcells in aGVHD, the mechanisms by which expression of these factors is restrained in UCB may underlie peripheral tolerance exhibited by UCB CD4+ T-cells and further the identification of risk factors or prophylactic treatments relevant to allogeneic transplantation. Following in these observations, our studies have led us to implicate a specific microRNA in the mechanism underlying restrained NFAT1 protein expression in UCB CD4+ graft T-cells. microRNA (miRNA) comprises a specialized subset of small cytoplasmic non-coding RNAs between 19-24 nucleotides in length. These highly-processed RNAs most frequently bind to regulatory sequences in the 3' untranslated region (UTR) of target mRNAs thus blocking gene expression by mediating mRNA degradation or translational repression. The latter scenario is thought to involve the RNA-induced silencing complex (RISC) and accumulation in translationdeficient but non-degradative complexes known as P-bodies 19. mRNAs sequestered into these complexes can be later re-targeted to translation initiation complexes or degraded through the decapping (Dcp) pathwa/o, a choice thought to be in part dependent on sequence complementarity, RNA secondary structure, and other signals. The activity of specific miRNAs has been associated with a wide variety of cellular differentiation pathways including hematopoiesis (reviewed in 21) and disease states such as cancer, diabetes 22 . 23 , and neurodegenerative diseases 24 . 25 • Notably, expression of miR-155 has been implicated in the regulation of mature T-cell lineage fate through c_Maf 6 . 27 and is associated with FoxP3mediated upregulation in Treg cells 28 • Here we provide evidence that a specific microRNA, miR-184, appears to contribute to the reduced NFAT1 protein in UCB-derived CD4+ T-cells. Expression of miR-184 is increased in human UCB CD4+ T-cells as compared to AB controls, and specifically represses activity in luciferase reporter assays. A converse relationship is observed between miR-184 activity and NFAT1 protein expression in both antisense interference and miRNA precursor "knock-in" models. This study comprises the first known demonstration of miR-184 expression and activity in primary human lymphocytes and suggests a novel role for cellular RNA interference in regulating the CD4+T-cell immune response in UCB.
MATERIALS AND METHODS
Cell isolation and culture. Acquisition of both AB and UCB units conformed to and was approved under University Hospital Case Medical Center IRB protocol nos. 02-00-34/CASE 11Z05 (rev. 11/13/07). Whole blood was obtained from umbilical cords immediately after delivery or by venipuncture from healthy adult donors and informed consent was obtained in accordance with the Declaration of Helsinki. Mononuclear cells were isolated following centrifugation through Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ) per manufacturer's instructions. CD4+ T-cells were then isolated via magnetic bead-labeling and separation (AutoMACS, Miltenyi Biotec, Auburn, CA) by first depleting the sample of CD14+ monocytes and then positively selecting for CD4+ cells, per manufacturer's recommendations. CD45RA+ na'ive T-cells were isolated via the Na'ive Human T-cell Isolation kit (Miltenyi). Purity as measured by flow cytometry was >90%. CD4+ T-cells were cultured in RPMI1640 medium containing 10% Fetal Bovine Serum (Gibco, Carlsbad, CA) supplemented with 2mM L-glutamine (Gibco). Where applicable, T -cells were stimulated in wells containing 1 J..lg/mL plate-bound aCD3 antibody and 5J..lg/mL soluble aCD28 antibody (BD Biosciences, San Jose, CA).
Western Blot. Cells were pelleted and lysed with radio-immunoprecipitation assay (RIPA) buffer. Following centrifugation, lysate supernatants were assayed for total protein content by modified Bradford assay (BioRad, Hercules, CA) per manufacturer's instructions. The Iysates were standardized for protein concentration, diluted with 4X SDS loading buffer containing [3- mercaptoethanol and heated to 95°C for 5 min. Equal volumes of samples were loaded into the wells of a 7.5% polyacrylamide SDS gel and run per standard protocol. The gel was then transferred to an Immobilon-P PVDF membrane (Millipore, Billerica, MA) via standard wettransfer protocol. Membrane was blocked with 5% dry milk, cut, and probed with primary antibodies to NFAT1 (BD Transduction Laboratories, San Jose, CA, #610703), then DNase treated (DNA-free™, Ambion, Austin, TX). Following DNase removal, cDNA was generated from RNA as described below for RT -PCR and subjected to 30 rounds of PCR per standard protocol with the following primers to verify the presence of the predicted targeted sequence: 5'-TTACTATTTGGACGGAACACC-3' (Reverse, both reactions), 5'-TATGAAACAGAATGACTGTGATC-3' (Forward, NM_012340 reaction), and 5'-CTACTTGGATGATGTTAATGAAAT-3' (Forward, NM_173091 reaction). These PCR reactions additionally generated 3' UTR sequences containing the full-length intervening sequence between the stop codon and the predicted miR-184 interacting site. This sequence (NM_012340 reaction only) was cloned into the pMIR-Report plasmid at the 3' UTR position following the luciferase gene per manufacturer's instructions (Ambion). Additionally, short (38-mer) synthesized DNA sequences matching the plus and minus-strand including and surrounding the predicted targeted site were dimerized and cloned into the same vector. "Control" denotes pMIR-Report without either insert. Sequences of each vector are shown in Figure S1 . as described and compared between UCB and AB samples (Figure 1 B) . These findings reveal only modest differences in relative NFA Tc2 mRNA quantity which are insufficient to account for the NFAT1 protein expression discrepancy in UCB versus AB CD4+ T cells.
Due to the dramatic differences in protein expression without significant corresponding differences in mRNA quantity, potential mechanisms of NFAT1 post-transcriptional regulation were investigated. Through proteasome inhibition and cellular fractionation experiments translocation of the NFATc2 mRNA into polysomes by UCB CD4+ cells was observed to lag behind AB CD4+ T -cells by at least 6h during in vitro stimulation ( Figure S2 ). Because similar effects have been observed in other confirmed miRNA-mRNA interractions 33 • 34 , and our previous microarray studies had failed to reveal significant differences in translational initiation or elongation factors we focused our subsequent work on identifying potential miRNA species that could specifically affect the translation of NFAT1 in UCB CD4+ T-cells.
miR·184 is predicted to interact strongly with the 3' UTR of the NFA Tc2 mRNA A search to determine specific miRNAs that may contribute to the observed differences in UCB CD4+ T-cell NFAT1 protein expression was conducted. Putative miRNA regulators were determined by querying the Sanger MicroCosm resource and miRBase targets registry. Many miRNA sequences predicted to bind to the 3' UTR of NFAT1 were identified by this computational analysis (highest-scoring candidates shown in Table 1 ). Of the 58 and 35
predicted micro-RNA binders (for each transcript variant, NCBI accession numbers NM_012340 and NM_173091, respectively) identified by this query, the strongest predicted binder to the 3' UTR (both variants) was miR-'j84, a recently characterized miRNA present in a variety of tissues 35 and suggested to be of importance in DNA methylation pathways36 and a potential antagonist of miR-205 37 • Conversely, the strongest predicted mRNA target of miR-184 (based on a reciprocal analysis of the miRNA sequence) was the previously identified sequence within the NFAT1 3' UTR ( Table 2 ). The NM_173091 variant lacks a 3' exon containing the miR·184 is more highly expressed in UCB than in AB CD4+ and decreases through early stimulation timepoints
The expression of miR-184 in unstimulated UCB CD4+ T-cells was on average quantified 58.4
times higher than in AB CD4+ T-cells by qRT-PCR ( Figure 3A) . Notably, neonatal CD4+ T-cells are known to contain a higher proportion of na"(ve recent thymic emigrants than AB 38 , although NFAT1 expression is lacking in both RA+ and RO+ subsets UCB and not expressed differently in either subset in AB17. The expression of miR-184 was observed to be much more highly skewed towards the na·ive (CD45RA+) CD4+ subset in AB than in UCB ( Figure S3 ).
The expression of miR-184 over a time course of in vitro simulation was also measured ( Figure   3B ). Subjecting isolated and stimulated UCB CD4+ T-cells to the same qRT-PCR assay at early timepoints revealed a modest decline in miR-184 quantity (40% of original by 6h). Later timepoints at which the eventual upregulation of NFAT1 protein expression is observable in UCB, but still dramatically lower compared to AB ( Figure 1A To determine whether miR-184 indeed interacts with the corresponding NFATc2 sequence as predicted ( Figure 2 ), expression vectors designed to transcribe a luciferase-encoding mRNA containing either a short synthetically-prepared sequence matching only the predicted miR-184 binding site from NFA Tc2 ("184-only") or the NFA Tc2 (NM_012340 variant) 3' UTR through and including the aforementioned sequence ("cloned UTR") were constructed. The full-length NFA Tc2 3' UTR has not been fully cloned or sequenced, and we wished to avoid the effects of any possible variations in UTR length between samples or cell types. These vectors were introduced into UCB ( Figure 4B ) and AB ( Figure 4C ) selected C04+ T-cells. Luciferase assays indicate only 38% and 60% expression compared to control when luciferase expression is influenced by the 184-only sequence and the cloned UTR, respectively ( Figure 4B ). This effect is almost completely reversed when a blocking antisense sequence to miR-184 is cotransfected. However in AB, the 184-only insertion has no effect on luciferase activity (middle column, white bar) while insertion of the cloned UTR results in a 58% reduction in expression ( Figure 4C ). Transfection of an exogenous precursor to miR-184 results in decreases of 61% and 23% respectively (middle bars). This effect is again attenuated when a blocking antisense sequence is co-transfected with the miR-184 precursor (rightmost bars). This data indicates that miR-184 does indeed modulate protein expression through its predicted binding site, and suggests significant endogenous miR-184 activity in UCB, but not AB C04+ T-cells.
To further confirm these observations, we mutated the "cloned UTR" luciferase expression vector insert used previously to disrupt either the seed region by removing the four 3'-most nucleotides from its predicted binding site (denoted "-seed region"), or the entire predicted binding site (denoted "-184 site"). Base-pair binding within the "seed" region has been shown to often be of importance to translational repression by miRNA39. We observed between a 4-and 3-fold induction, respectively, of luciferase expression in UCB C04+ cells when either the seed region or the miR-184 binding site was removed ( Figure 40 ). However, we only observed a comparatively slight (1.5-fold) increase in expression when the same vectors were transfected into AB C04+ cells ( Figure 4E ). Failure to observe a significant change in lucifierse expression with inhibition of miR-184 activity in UCB or introduction of miR-184 in AB (grey bars) confirmed the specificity of the observed effect.
miR-184 activity directly affects NFAT1 protein quantity in unstimulated CD4+ T-cells
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To determine whether endogenous miR-184 can directly repress NFAT1 protein expression in UCB C04+ T-cells, Western blot for NFAT1 was performed on unstimulated selected C04+ Tcells following transfection with either control or blocking antisense to miR-184 ( Figure SA 
miR-184 activity conversely affects production of the NFAT-associated IL-2 transcript
To determine whether manipulation of NFAT1 protein levels through interference with the activity of miR-184 is sufficient to result in an increase in transcription of NFAT1-target genes, the transcription of Interleukin 2 (IL-2), a gene strongly activated by NFAT1 binding to its promoter following stimulation 14, was assayed by qRT-PCR. UCB C04+ cells were transfected with blocking antisense to miR-184, assayed for upregulated NFAT1 expression by Western blot (data included in Figure SA ) after 16h and then stimulated in vitro as described previously. Data reflects a significantly greater amount of IL-2 mRNA in the miR-184 antisense-treated samples by 6h of stimulation which is maintained through 16h ( Figure 6A ). Conversely, AB C04+ T-cells transfected with an exogenous miR-184 precursor exhibited dramatically reduced IL-2 transcription through the same stimulation timepoints ( Figure 6B ). These findings indicate that 14 miR-184 interference with NFAT1 in UCB CD4+ T-cells is indeed sufficientto influence both NFAT1 protein levels and transcription of the known NFAT1 target gene IL-2.
DISCUSSION
Our findings comprise the first observation of miR-184 activity in immune cells and a characterization of its activity on a key transcriptional regulator of inflammation specifically known to exhibit decreased activity in UCB CD4+ T-cells. We identified miR-184 as a strong predicted regulator of NFAT1 and confirmed its interaction with the observed complementary binding site within the NFATc2 mRNA 3' UTR. UCB CD4+ T-cells were shown to exhibit significantly more miR-184 RNA and miR-184-mediated repressive activity than AB CD4+ Tcells. We additionally confirmed through blocking and gain-of-function analyses that manipulation of miR-184 is sufficient to influence NFAT1 protein as well as its known downstream target, IL-2. cells. Multiple miRNA species are predicted to bind sites proximal to and overlapping with the miR-184 binding site, therefore a yet-to-be-identified miRNA may modulate the initiation of NFAT1 protein translation at later timepoints. In AB CD4+ cells, it is foreseeable that the already higher expression of NFAT1 protein ( Figure 1A ) and the relatively lower expression of miR-184 at rest ( Figure 3A ) and its decrease in expression over stimulation ( Figure 3C ), combined with increasing expression of NFA Tc2 mRNA at early stimulation timepoints (Figure 1 B) Additional predicted miR-184-interacting transcripts include the transcription factor LM01 associated with T-cell leukemia and the extensively characterized oncogene MPL, as well as a host of genes not yet characterized in immune cells but in some cases not tightly restricted to particular cell lineages ( Table 2) . We have observed MPL to be expressed significantly lower in UCS CD4+ cells compared to AS by microarray (unpublished data); however, due to the complex and poorly-understood nature of degradative versus non-degradative mechanisms involved in miRNAlmRNA interactions it is clear that analyses based on simple mRNA quantification may fail to elucidate the true role of miRNA. It is often assumed that weaker complementarity in general results in a less-degradative fate for the mRNA, but it is unlikely that a discrete binding affinity threshold exists for transcript degradation across miRNAs, transcripts and cell types.
As specific miRNAs and miRNA families are currently being widely proposed as biomarkers for various cancers, future implications for this work may include graft selection, ex vivo graft manipulation and targeted therapy of hematologic malignancies. Pharmacological targeting of NFAT1 as a key regulator of the autoimmune/inflammatory response is well-described: CsA and FK506 (tacrolimus), which separately disrupt the calcineurin/calmodulin signaling interaction preventing NFAT1 nuclear translocation, have been used as therapeutic prophylaxis and treatment for aGVHD for decades, However, these treatments exhibit toxic calcineurin/NFATindependent side effects, particularly in the nephritic and circulatory systems in addition to the traditional infection considerations of immunosuppressive therapy. GVHD still remains the major limitation to successful allogeneic transplantation, and directed molecular T-cell targeting therapies could potentially alleviate some significant toxicities of pharmacologic immunosuppressive calcineurin inhibitors.
In summary, miR-184 is capable of regulating NFAT1 protein expression without causing transcript degradation through its predicted complementary binding site within the NFA Tc2 
